New eczema pill shows promise in early safety trial

NCT ID NCT07336940

Completed Symptom relief Sponsor: Enveda Therapeutics Source: ClinicalTrials.gov ↗

First seen Jan 14, 2026 · Last updated May 16, 2026 · Updated 14 times

Summary

This early-stage study tested a new drug called ENV-294 in 9 adults with moderate-to-severe atopic dermatitis (eczema). The main goal was to see if the drug is safe and tolerable when taken daily for 28 days. Researchers also looked for any changes in eczema severity. This is a first step to see if ENV-294 might help control eczema symptoms.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (AD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Center for Dermatology Clinical Research, Inc.

Fremont, California, 94538, United States
J & S Studies

College Station, Texas, 77845, United States
Skin Sciences, PLLC

Louisville, Kentucky, 40217, United States
Texas Dermatology and Laser Specialists

San Antonio, Texas, 78218, United States
Virginia Dermatology & Skin Cancer Center

Norfolk, Virginia, 23502, United States

Conditions

Explore the condition pages connected to this study.

ATOPIC DERMATITIS (AD)